Table 1.

Characteristics and demographics of patients treated with raltegravir and a control population naïve to HAART

Characteristics	Raltegravir patients N = 32	Controls N = 64
Male gender	21 (65.6%)	42 (65.6%)
Age at time of index date, median (IQR), years	50.8 (42.5–55.1)	47.3 (40.5–56.3)
Race
Caucasian	23 (71.9%)	46 (71.9%)
Black	7 (21.9%)	14 (21.9%)
Other	2 (6.2%)	4 (6.2%)
Route of HIV infection
Men who have sex with men	15 (46.9%)	30 (46.9%)
Heterosexually infected	17 (53.1%)	34 (53.1%)
Injection drug user	None	None
Other	None	None
Diagnosed with HIV before 1 January 1995	9 (28.1%)	5 (7.8%)
CD4 cell count at index date, median (IQR), cells/μL	280 (60–291)	221 (181–472)
Viral load at index date, median (IQR), log10 copies/mL	2.45 (1.60–3.16)	4.40 (3.24–5.46)
Time from HIV diagnosis to index date, median (IQR), years	15.3 (12.5–18.8)	0.2 (0.1–3.4)
Time from HAART start to index date, median (IQR), years	10.7 (10.0–11.3)	–
One or more AIDS-defining events prior to index date	14 (43.8%)	11 (17.2%)

Abbreviations: IQR, interquartile range.